Genomic strategies for drug repurposing.

J Egypt Natl Canc Inst

Department of Life Sciences, Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat, India.

Published: November 2024

AI Article Synopsis

  • - Functional genomics combines various scientific fields to study gene functions and their relevance in understanding diseases and developing new medications, particularly through drug repurposing, which leverages existing drugs for new therapeutic uses.
  • - Techniques such as gene expression profiling and Mendelian randomization help identify potential drugs by analyzing the molecular characteristics of diseases, while advances in computer science enable efficient data modeling of gene expression networks.
  • - Despite a wealth of existing research, functional genomics in cancer drug discovery remains underexplored, with next-generation sequencing and proteomics offering promising opportunities to enhance therapeutic advancements through publicly available databases and mining techniques.

Article Abstract

Functional genomics, a multidisciplinary subject, investigates the functions of genes and their products in biological systems to better understand diseases and find new drugs. Drug repurposing is an economically efficient approach that entails discovering novel therapeutic applications for already-available medications. Genomics enables the identification of illness and therapeutic molecular characteristics and interactions, which in turn facilitates the process of drug repurposing. Techniques like gene expression profiling and Mendelian randomization are helpful in identifying possible medication candidates. Progress in computer science allows for the investigation and modeling of gene expression networks that involve large amounts of data. The amalgamation of data concerning DNA, RNA, and protein functions bears similarity to pharmacogenomics, a crucial aspect in crafting cancer therapeutics. Functional genomics in drug discovery, particularly for cancer, is still not thoroughly investigated, despite the existence of a significant amount of literature on the subject. Next-generation sequencing and proteomics present highly intriguing opportunities. Publicly available databases and mining techniques facilitate the development of cancer treatments based on functional genomics. Broadening the exploration and utilization of functional genomics holds significant potential for advancing drug discovery and repurposing, particularly within the realm of oncology.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s43046-024-00245-zDOI Listing

Publication Analysis

Top Keywords

functional genomics
16
drug repurposing
12
gene expression
8
drug discovery
8
drug
5
genomics
5
genomic strategies
4
strategies drug
4
repurposing
4
functional
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

GSK R&D, Stevenage, Hertfordshire, United Kingdom.

Background: Genetic variants in GRN, the gene encoding progranulin, are causal for or are associated with the risk of multiple neurodegenerative diseases. Modulating progranulin has been considered as a therapeutic strategy for neurodegenerative diseases including Frontotemporal Dementia (FTD) and Alzheimer's Disease (AD). Here, we integrated genetics with proteomic data to determine the causal human evidence for the therapeutic benefit of modulating progranulin in AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sage Bionetworks, Seattle, WA, USA.

Background: There is an urgent need for new therapeutic and diagnostic targets for Alzheimer's disease (AD). Dementia afflicts roughly 55 million individuals worldwide, and the prevalence is increasing with longer lifespans and the absence of preventive therapies. Given the demonstrated heterogeneity of Alzheimer's disease in biological and genetic components, it is critical to identify new therapeutic approaches.

View Article and Find Full Text PDF

Background: Genome-wide association studies (GWAS) have identified close to one hundred loci associated with Alzheimer's disease (AD) risk. However, for most of these loci we do not understand the underlying mechanism leading to disease. Crispr genome editing in human induced pluripotent stem cells (hiPSCs) provides a model system to study the effects of these genetic variants in a disease relevant cell type.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Neuroscience and Aging Research Unit, Institute of Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.

Background: Historically, efforts to engage under-represented communities in health research have encountered limited success, attributable to inadequate community participation, acceptability, and ownership. Globally, an innovative strategy to foster community involvement in research is the establishment of Community Advisory Boards (CABs). These boards consist of stakeholders from the target community, providing partnership and support throughout all phases of the research, from conception to implementation and evaluation.

View Article and Find Full Text PDF

Background: Black Americans (BAs), Hispanics/Latinos (H/Ls), and Africans (As) face a disproportionate burden of aging and Alzheimer's Disease and Related Dementias (AD/ADRD), coupled with underrepresentation in research. Further, researchers also report a lack of compliance on sensitive social determinants of health data for AD/ADRD research. For instance, the PRAPARE tool reports a low completion rate in community and clinical settings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!